Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.18
STXS's Cash to Debt is ranked lower than
86% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. STXS: 0.18 )
Ranked among companies with meaningful Cash to Debt only.
STXS' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.76 Max: N/A
Current: 0.18
Equity to Asset -1.33
STXS's Equity to Asset is ranked lower than
97% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. STXS: -1.33 )
Ranked among companies with meaningful Equity to Asset only.
STXS' s Equity to Asset Range Over the Past 10 Years
Min: -1.33  Med: -0.1 Max: 0.82
Current: -1.33
-1.33
0.82
F-Score: 3
Z-Score: -39.26
M-Score: -4.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -15.43
STXS's Operating margin (%) is ranked lower than
70% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. STXS: -15.43 )
Ranked among companies with meaningful Operating margin (%) only.
STXS' s Operating margin (%) Range Over the Past 10 Years
Min: -171.64  Med: -40.84 Max: -14.36
Current: -15.43
-171.64
-14.36
Net-margin (%) -20.82
STXS's Net-margin (%) is ranked lower than
70% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. STXS: -20.82 )
Ranked among companies with meaningful Net-margin (%) only.
STXS' s Net-margin (%) Range Over the Past 10 Years
Min: -180.79  Med: -65.02 Max: -14.86
Current: -20.82
-180.79
-14.86
ROA (%) -40.82
STXS's ROA (%) is ranked lower than
85% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. STXS: -40.82 )
Ranked among companies with meaningful ROA (%) only.
STXS' s ROA (%) Range Over the Past 10 Years
Min: -217.44  Med: -54.1 Max: -18.93
Current: -40.82
-217.44
-18.93
ROC (Joel Greenblatt) (%) -396.02
STXS's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. STXS: -396.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
STXS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3377.46  Med: -465.8 Max: -77.3
Current: -396.02
-3377.46
-77.3
Revenue Growth (3Y)(%) -35.70
STXS's Revenue Growth (3Y)(%) is ranked lower than
94% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. STXS: -35.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
STXS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -13.95 Max: 218.4
Current: -35.7
0
218.4
EBITDA Growth (3Y)(%) 14.70
STXS's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. STXS: 14.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
STXS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -77.2  Med: -33.95 Max: 19.6
Current: 14.7
-77.2
19.6
EPS Growth (3Y)(%) -35.90
STXS's EPS Growth (3Y)(%) is ranked lower than
90% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. STXS: -35.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
STXS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.6  Med: -34.7 Max: 17.2
Current: -35.9
-64.6
17.2
» STXS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

STXS Guru Trades in

STXS Guru Trades in

STXS Guru Trades in

Q2 2016

STXS Guru Trades in Q2 2016

Jim Simons 248,700 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with STXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:SKLN, OTCPK:REPR, OTCPK:UEEC, NAS:DXTR, OTCPK:LDSYF, NAS:AKER, OTCBB:NEPH, NAS:NURO, NAS:PDEX, NAS:BMRA, NAS:SSKN, OTCPK:PEYE, OTCPK:IRSB, OTCPK:RSCF, NAS:BLFS, OTCPK:ECIA, OTCPK:SOAN, OTCPK:ASNB, OTCPK:WHSI, OTCPK:QTXB » details
Traded in other countries:RJR1.Germany,
Stereotaxis Inc designs, manufactures and markets an cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease.

Stereotaxis Inc was incorporated in Delaware on June 1990. The Company designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. The core components of the Niobe system have received regulatory clearance in the U.S., Canada Europe, and various other countries. In addition to the Niobe system and its components, the Company also has developed the Odyssey Solution, which consolidates the multiple sources of diagnostic and imaging information found in the interventional lab into a large-screen user interface with single mouse control, which could be connected via a private network line to other interventional labs or to a remote clinical call center. The system also features a remote viewing and recording capability, called Odyssey Cinema, which simultaneously captures procedure data from multiple sources. The tool includes an archiving capability that would allow clinicians to store and replay entire procedures or segments of procedures. This information could be accessed from locations throughout the hospital local area network and over the global Odyssey network providing physicians with a tool for clinical collaboration, remote consultation and training. The Company operates mainly in the U.S., Europe and Asia and it continues to sell its products both within and outside of the U.S. It markets its products in the U.S and internationally through a direct sales force of senior sales specialists, distributors and sales agents, supported by account managers and clinical specialists that provide training, clinical support, and other services to its customers. The markets for medical devices are intensely competitive and are characterized by rapid technological advances, frequent new product introductions, evolving industry standards and price erosion. It faces competition from companies that are developing new approaches and products for use in interventional procedures, including robotic approaches that are directly competitive with its technology. It also faces competition from companies who currently market or are developing drugs, gene or cellular therapies to treat the conditions for which the Company's products are intended.

Ratios

vs
industry
vs
history
P/S 0.48
STXS's P/S is ranked higher than
94% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. STXS: 0.48 )
Ranked among companies with meaningful P/S only.
STXS' s P/S Range Over the Past 10 Years
Min: 0.15  Med: 2.91 Max: 35.41
Current: 0.48
0.15
35.41
PFCF 10.54
STXS's PFCF is ranked higher than
94% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.58 vs. STXS: 10.54 )
Ranked among companies with meaningful PFCF only.
STXS' s PFCF Range Over the Past 10 Years
Min: 7.86  Med: 14.8 Max: 22.53
Current: 10.54
7.86
22.53
Current Ratio 0.78
STXS's Current Ratio is ranked lower than
93% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. STXS: 0.78 )
Ranked among companies with meaningful Current Ratio only.
STXS' s Current Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.08 Max: 5.72
Current: 0.78
0.61
5.72
Quick Ratio 0.50
STXS's Quick Ratio is ranked lower than
93% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. STXS: 0.50 )
Ranked among companies with meaningful Quick Ratio only.
STXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.89 Max: 5.39
Current: 0.5
0.47
5.39
Days Inventory 223.46
STXS's Days Inventory is ranked lower than
83% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. STXS: 223.46 )
Ranked among companies with meaningful Days Inventory only.
STXS' s Days Inventory Range Over the Past 10 Years
Min: 115.43  Med: 178.88 Max: 250.42
Current: 223.46
115.43
250.42
Days Sales Outstanding 52.74
STXS's Days Sales Outstanding is ranked higher than
67% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. STXS: 52.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
STXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.74  Med: 89.38 Max: 205.12
Current: 52.74
52.74
205.12
Days Payable 108.87
STXS's Days Payable is ranked higher than
81% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. STXS: 108.87 )
Ranked among companies with meaningful Days Payable only.
STXS' s Days Payable Range Over the Past 10 Years
Min: 64.34  Med: 116.98 Max: 206.27
Current: 108.87
64.34
206.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.10
STXS's 3-Year Average Share Buyback Ratio is ranked lower than
91% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. STXS: -36.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
STXS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -289.3  Med: -26.5 Max: -10.6
Current: -36.1
-289.3
-10.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.17
STXS's Price/Median PS Value is ranked higher than
98% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. STXS: 0.17 )
Ranked among companies with meaningful Price/Median PS Value only.
STXS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 1.12 Max: 12.06
Current: 0.17
0.07
12.06
Earnings Yield (Greenblatt) (%) -11.56
STXS's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. STXS: -11.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
STXS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.26  Med: 18.7 Max: 22.9
Current: -11.56
-13.26
22.9

More Statistics

Revenue (TTM) (Mil) $35.00
EPS (TTM) $ -0.35
Beta1.57
Short Percentage of Float1.34%
52-Week Range $0.54 - 1.95
Shares Outstanding (Mil)21.85
» More Articles for STXS

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: NBN, EMMS, STXS, FOE, NVTL May 21 2012 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,800 Shares Jan 04 2011 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 05 2010 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,500 Shares May 11 2010 
Stereotaxis Inc. (STXS) CFO Daniel J Johnston buys 10,000 Shares May 10 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) May 07 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 06 2009 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 1,410 Shares Sep 03 2009 
Stereotaxis Inc. Reports Operating Results (10-Q) Aug 07 2009 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,300 Shares Jun 04 2009 

More From Other Websites
STEREOTAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Sep 28 2016
Stereotaxis secures $24 million in equity financing Sep 27 2016
Stereotaxis Announces Multiple Positive Strategic Updates Sep 27 2016
ETF’s with exposure to Stereotaxis, Inc. : September 12, 2016 Sep 12 2016
STEREOTAXIS, INC. Financials Aug 23 2016
ETF’s with exposure to Stereotaxis, Inc. : August 23, 2016 Aug 23 2016
Stereotaxis posts wider loss as system sales plummet Aug 12 2016
Stereotaxis, Inc. :STXS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 Aug 11 2016
STEREOTAXIS, INC. Files SEC form 10-Q, Quarterly Report Aug 10 2016
Stereotaxis Completes Niobe® System Installation at Kakogawa Hospital Aug 09 2016
Stereotaxis Reports 2016 Second Quarter Financial Results Aug 09 2016
STEREOTAXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 09 2016
Stereotaxis Completes Niobe® System Installation at Kakogawa Hospital Aug 09 2016
Stereotaxis Reports 2016 Second Quarter Financial Results Aug 09 2016
Q2 2016 Stereotaxis Inc Earnings Release - After Market Close Aug 09 2016
OTC Markets Group Welcomes Stereotaxis, Inc. to OTCQX Aug 04 2016
Stereotaxis Common Stock to Begin Trading on OTCQX on August 4, 2016 Aug 03 2016
STEREOTAXIS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Aug 03 2016
Stereotaxis Common Stock to Begin Trading on OTCQX on August 4, 2016 Aug 03 2016
Stereotaxis to Report Second Quarter 2016 Financial Results on August 9, 2016 Aug 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)